We have to take into account Gilead's dishonesty in the way it presents it's trial results.
And, remember, Gilead bought the company that created Sofosbuvir. They then quietly changed the product, making it slightly inferior but giving it a better shelf life, after trialling it. They then created their own NS5A inhibitor, Ledipasvir. It has a lower kill log than Daclatasvir, but Gilead's power and persuasion have made it's combination with Sovaldi (Harvoni) the market leader and preferred medicine for many heppers.
Frankly, if a Gilead exec shook my hand (unlikely, I know), I'd check how many fingers I had left.